전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
cabozantinib
kabozantinib
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cabozantinib was metabolized in vivo.
kabozantinib byl metabolizován in vivo.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cabozantinib is a cyp3a4 substrate.
kabozantinib je substrátem cyp3a4.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cometriq 20 mg hard capsules cabozantinib
cometriq 20 mg tvrdé tobolky cabozantinibum
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
hemorrhage has been observed with cabozantinib.
při používaní kabozantinibu byla pozorována hemoragie.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
lapatinib nilotinib erlotinib dabrafenib cabozantinib
dasatinib lapatinib nilotinib erlotinib dabrafenib cabozantinib
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cabometyx contains the active substance cabozantinib.
cabometyx obsahuje léčivou látku kabozantinib.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cabometyx 20 mg film-coated tablets cabozantinib
cabometyx 20 mg potahované tablety cabozantinibum
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
table 1: adverse reactions reported with cabozantinib
tabulka 1: nežádoucí účinky hlášené při užívání kabozantinibu
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
the active substance is cabozantinib (s)-malate.
léčivou látkou je cabozantinibi malas.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cabozantinib should be discontinued in patients who experience onj.
u pacientů s onj se má užívání kabozantinibu přerušit.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
fatal haemorrhages have occurred in the cabozantinib clinical program.
v klinickém programu podávání kabozantinibu došlo ke krvácení s fatálním vyústěním.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cometriq 20 mg hard capsules cometriq 80 mg hard capsules cabozantinib
cometriq 20 mg tvrdé tobolky cometriq 80 mg tvrdé tobolky cabozantinibum
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cabozantinib should be discontinued in patients who develop nephrotic syndrome.
pokud se u pacienta rozvine nefrotický syndrom, kabozantinib se musí přestat podávat.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
adverse reactions such as fatigue and weakness have been associated with cabozantinib.
s kabozantinibem se však pojí nežádoucí účinky jako únava a slabost.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
administration of mrp2 inhibitors may result in increases in cabozantinib plasma concentrations.
podávání inhibitorů mrp2 může způsobit zvýšení plazmatických koncentrací kabozantinibu.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
events of osteonecrosis of the jaw (onj) have been observed with cabozantinib.
při použití kabozantinibu byly pozorovány případy osteonekrózy čelisti (onj).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
each tablet contains cabozantinib (s)-malate equivalent to 20 mg cabozantinib.
jedna tableta obsahuje cabozantinibi malas v množství ekvivalentním cabozantinibum 20 mg.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
each tablet contains cabozantinib (s)-malate equivalent to 20 mg of cabozantinib.
jedna tableta obsahuje cabozantinibi malas v množství ekvivalentním cabozantinibum 20 mg.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
each hard capsule contains cabozantinib (s)-malate equivalent to 20 mg of cabozantinib.
jedna tvrdá tobolka obsahuje cabozantinibi malas ekvivalentní cabozantinibum 20 mg.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: